Myant corp. Expands into US Market with Acquisition of mmHg Inc.
Table of Contents
Canadian health technology innovator Myant Corp. announced its acquisition of mmHg Inc., a leading US digital health company specializing in remote blood pressure monitoring and cardiovascular risk management. This strategic move substantially expands Myant’s reach into the lucrative American healthcare market, leveraging mmHg’s established customer base and partnerships, including a key collaboration with A&D Medical, a major medical device manufacturer.
The acquisition underscores Myant’s commitment to its “prevention through precision” strategy,a forward-thinking approach to personalized,AI-driven remote patient care. This initiative aims to revolutionize how chronic diseases are managed and prevented.
mmHg’s platform offers healthcare providers a powerful tool for efficient, guideline-compliant cardiovascular health management, particularly beneficial in underserved areas. The platform’s innovative software allows for remote tracking and analysis of vital cardiovascular data, enabling more precise interventions and improved patient outcomes. The technology is already trusted by leading North American institutions, including Beth Israel Deaconess (Harvard Medical), Johns Hopkins, Columbia University, NYU, Tulane University, and the University of British Columbia, for both patient care and research purposes.
By integrating mmHg’s remote monitoring capabilities with Myant’s cutting-edge textile computing technology, healthcare professionals gain access to continuous, real-time patient data. This allows for earlier detection of health risks, personalized treatment plans, and improved chronic disease management, ultimately leading to better health outcomes, reduced hospitalizations, and enhanced quality of life.
“Our company is committed to making healthy aging a reality for millions of people. We want to declare war on chronic diseases and redefine what it means to grow older. This acquisition enhances our ability to provide comprehensive cardiovascular monitoring and risk management solutions,” said Tony Chahine,CEO of Myant. “In doing so, we are strengthening our role in transforming digital health and enabling this large, aging population to live younger and longer.”
Peter Wood, co-founder and chief operating officer of mmHg Inc., added, “The combination of Myant’s innovative textile technology and mmHg’s clinically sound software architecture will undoubtedly create the next generation of personalized care delivery, where patients will be able to transmit clinically relevant, continuous vital data to a platform that delivers the data in an efficient and clinically relevant way for care teams.”
This acquisition further solidifies Myant’s position as a leader in leveraging AI and advanced materials to improve patient care and extend lifespan. The integration of mmHg’s capabilities enhances Myant’s already comprehensive, vertically integrated solutions.
About Myant Corp.
Myant is dedicated to improving quality of life through advancements in AI, medicine, and advanced materials. Their focus spans health, safety, connection, and confidence across all life stages. myant envisions a future where AI-powered “guardians,” integrated into comfortable textile interfaces, enhance human capabilities and seamlessly interact with the digital world. In 2024,Myant expanded into the European Union and appointed Dr. Xin Gao as its Chief AI Officer.
About mmHg Inc.
mmHg Inc. is a digital health company specializing in remote blood pressure monitoring and cardiovascular risk management.Co-developed by Dr. Raj Padwal,a renowned expert in cardiovascular health,their solutions are designed to improve clinical care and are widely used by healthcare providers and researchers across North America.
Myant at CES 2025
Visit Myant at booth 53618 at the Venetian Expo & Convention Centre in Las Vegas, Nevada, from January 7-10, 2025.
for more data,contact Charles Andreo at info@myant.ca.
Myant Acquires mmHg Inc., Bolstering Precision Medicine in Cardiovascular Care
Myant, a leader in textile-based bio-sensing technology, announced its acquisition of mmHg inc., a significant move designed to enhance precision medicine solutions for cardiovascular health. This strategic acquisition combines Myant’s expertise in wearable sensor technology with mmHg’s focus on data-driven insights, promising advancements in patient monitoring and personalized care.
The merger is expected to accelerate the development of innovative tools for early disease detection and personalized treatment plans. This is particularly crucial in the U.S., where cardiovascular disease remains a leading cause of death. By combining their resources, Myant and mmHg aim to improve patient outcomes and reduce healthcare costs associated with managing heart conditions.
Improving Cardiovascular Care through Technology
Myant’s technology focuses on creating comfortable and unobtrusive wearable sensors woven directly into clothing. These sensors continuously monitor vital signs, providing real-time data that can be used to detect potential problems before they escalate. mmHg’s expertise in data analytics will be instrumental in interpreting this data, allowing healthcare providers to make more informed decisions about patient care.
The combined entity will focus on developing advanced diagnostic tools and personalized treatment strategies. This could lead to earlier interventions, preventing serious complications and improving the overall quality of life for patients with cardiovascular conditions. The potential impact on the U.S.healthcare system is ample, offering the possibility of more efficient and effective care.
While specific details about the integration process and future product development remain undisclosed, the acquisition signals a significant step forward in the request of technology to improve cardiovascular health. The combined strengths of Myant and mmHg position them to become a major player in the rapidly evolving field of precision medicine.
Myant Corp. Enhances US Presence with Acquisition of mmHg Inc., Leading to More Precise cardiovascular Care
This move by Myant, a pioneer in textile-based bio-sensing technology, and mmHg, a US digital health company known for its remote blood pressure monitoring, promises exciting possibilities for improved cardiovascular health management through personalized and proactive care.
Interview with Dr. Alastair Smith, Cardiologist and Digital Healthcare Expert
World-Today-News Senior Editor: Dr. Smith, Myant’s acquisition of mmHg appears to be making significant waves in the healthcare industry. What are your initial thoughts on this growth?
Dr. Smith: It’s definitely a noteworthy move. The convergence of Myant’s expertise in wearable sensor technology and mmHg’s robust data analytics platform holds immense potential for revolutionizing cardiovascular care. We’re seeing a shift towards proactive, personalized medicine, and this partnership seems perfectly positioned to accelerate that trend.
World-Today-News senior Editor: Can you explain the significance of this “precision medicine” approach,especially in the context of cardiovascular health?
Dr. Smith: Traditionally, cardiovascular care has been reactive, treating conditions after they’ve manifested. Precision medicine aims to change that by using real-time data to identify individual risk factors and implement preemptive measures. Imagine continuous monitoring of vital signs through cozy wearables, coupled with AI-powered analysis that flags potential issues before they escalate into serious problems. That’s the power of precision medicine.
World-Today-News Senior Editor: How could this acquisition directly impact patients with cardiovascular disease?
Dr. Smith: The potential benefits for patients are immense. continuous monitoring can lead to earlier detection of irregularities, allowing for timely interventions and potentially preventing heart attacks or strokes. Personalized treatment plans based on individual data can improve medication adherence and overall disease management.Ultimately, this could translate into longer, healthier lives for millions of people.
World-Today-News Senior Editor: What challenges might Myant and mmHg face in implementing this vision?
Dr. Smith: Integrating these complex technologies into clinical workflows requires careful planning and collaboration with healthcare providers. Ensuring data privacy and security is crucial.Addressing potential biases in AI algorithms must be a top priority. Overcoming these challenges will be key to the success of this initiative.
World-Today-News Senior Editor: Looking ahead, what future applications do you envision for this merged company in the realm of healthcare?
Dr. Smith: This is just the beginning. I anticipate seeing Myant and mmHg’s technology expand beyond cardiovascular health into other chronic conditions like diabetes and respiratory diseases. They could play a pivotal role in wearable health monitoring becoming an integral part of standard care, leading to a more proactive and preventative approach to healthcare overall.
